Abstracts tagged "anti-TNF therapy and axial spondyloarthritis"

Abstract Number: 1538 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Early Versus Delayed Anti-TNF-α Treatment in Axial Spondyloarthritis
Herman F Mann¹, Jakub Zavada², Šárka Forejtová³, Lenka Szczukova⁴, Zlatuše Křístková⁴ and Karel Pavelka¹, ¹ATTRA, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Czech Republic, Prague, Czech Republic, ⁴Institute of Biostatistics and Analyses. Faculty of Medicine, Masaryk University, Brno, Czech Republic
Background/Purpose: Anti-TNF-α agents are the mainstay of pharmacotherapy for patients with axial spondyloarthritis (AxSpA) who failed treatment with NSAIDs. A little is known about the…
Abstract Number: 710 • 2016 ACR/ARHP Annual Meeting
Patient-Reported Quality of Life in Patients with Baseline Objective Signs of Inflammation and Active Nonradiographic Axial Spondyloarthritis Treated with Golimumab: Results of the Open-Label Extension of a Randomized, Double-Blind Study
Walter Maksymowych¹, Maxime Dougados², Joachim Sieper³, Jürgen Braun⁴, G Bergman⁵, Sean P. Curtis⁶, Anjela Tzontcheva⁶, George Philip⁶, Susan Huyck⁶ and Désirée van der Heijde⁷, ¹Medicine, University of Alberta,, Edmonton, AB, Canada, ²Paris-Descartes University, Paris, France, ³Rheumatology Department, Charité – University Medicine Berlin, Berlin, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Merck & Co., Inc., Whitehouse Station, NJ, ⁶Merck & Co., Inc., Kenilworth, NJ, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In an open-label extension (OLE) of a 16-week, randomized, double blind (DB), placebo (PBO)-controlled, phase 3 study (GO-AHEAD; NCT1453725) in patients with nonradiographic axial…
Abstract Number: 2580 • 2014 ACR/ARHP Annual Meeting
A Comparison of Baseline Characteristics and Real-Life Effectiveness of Anti-TNF Therapy in Non-Radiographic Axial Spondyloarthritis Versus Ankylosing Spondylitis – a Single Center Cohort Study
Sarka Forejtova¹, Jakub Zavada², Michal Uher³, Karel Hejduk³ and Karel Pavelka⁴, ¹Rheumatology, Institute of Rheumatology, Prague, Czech Republic, ²Charles University, Prague, Czech Republic, ³Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
Background/Purpose: The recent Assessment of SpondyloArthritis international Society (ASAS) classification criteria proposed the concept of axial spondylarthritis (axSpA) to enable earlier treatment not only for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].